Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Better Therapeutics Inc BTTX

Healthcare Medical Devices
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software... see more

Recent & Breaking News (PINL:BTTX)

Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq

Business Wire March 14, 2024

Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers

Business Wire March 5, 2024

Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Business Wire March 4, 2024

Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Accesswire March 1, 2024

Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease

Business Wire February 20, 2024

Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment

Business Wire February 6, 2024

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Business Wire January 4, 2024

Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease

Business Wire January 2, 2024

Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions

Business Wire November 28, 2023

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Business Wire November 14, 2023

Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Business Wire November 9, 2023

Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023

Business Wire November 8, 2023

Better Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual Conference

Business Wire October 26, 2023

Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes

Business Wire October 16, 2023

Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes

Business Wire October 11, 2023

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances

Business Wire October 5, 2023

Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes

Business Wire September 28, 2023

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Business Wire August 9, 2023

Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023

Business Wire August 2, 2023

Better Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per Share

Business Wire July 25, 2023